What this study adds
- CoQ10 at 300 mg/day over one cycle of treatment did not change
doxorubicin pharmacokinetics for breast cancer patients.
- Co-administration of doxorubicin and CoQ10 at 300 mg/day did not
increase treatment-related serious adverse events for breast cancer
patients.
- Poor accrual to this trial demonstrates the challenge of testing CoQ10
with concurrent chemotherapy and warrants future studies to replicate
and extend study results.